secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001493152-25-028296
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma gets IRB approval for Phase 1b norovirus challenge study with CDI-988; enrollment starts Q1 2026
--------------------------------------------------------------------------------

- IRB approval from Emory University to initiate Phase 1b human challenge study with CDI-988 for norovirus prevention and treatment.
- Enrollment expected to begin Q1 2026; study involves up to 40 healthy subjects ages 18-49.
- CDI-988 is first oral broad-spectrum antiviral for norovirus; no approved treatments or vaccines currently exist.
- Study is randomized, double-blind, placebo-controlled; primary endpoint is reduction in clinical symptoms.
- Follows prior FDA clearance of IND and favorable Phase 1 safety data from August 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315225028296/0001493152-25-028296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315225028296/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-028296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer